| Drug Name |
Tobramycin sulfate |
| Drug ID |
BADD_D02233 |
| Description |
Aminoglycosides, many of which are derived directly from _Streptomyces_ spp., are concentration-dependent bactericidal antibiotics with a broad spectrum of activity against Gram-positive and Gram-negative organisms.[A232294] Inhaled tobramycin is notable for its use in treating chronic _Pseudomonas aeruginosa_ infections in cystic fibrosis patients, as _P. aeruginosa_ is notoriously inherently resistant to many antibiotics.[A232294, A232299, L32739] However, tobramycin can also be administered intravenously and topically to treat a variety of infections caused by susceptible bacteria.[L32744, L32749] Its use is limited in some cases by characteristic toxicities such as nephrotoxicity and ototoxicity, yet it remains a valuable option in the face of growing resistance to front-line antibiotics such as β-lactams and cephalosporins.[A232294, A232349, L32739, L32749]
Tobramycin was approved by the FDA in 1975 and is currently available in a variety of forms for administration by inhalation, injection, and external application to the eye (ophthalmic).[L32739, L32744, L32749] |
| Indications and Usage |
For the treatment of pseudomonas aeruginosa lung infections. Also being investigated for use in the treatment of sinus infections. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
J01GB01; S01AA12 |
| DrugBank ID |
DB00684
|
| KEGG ID |
D02542
|
| MeSH ID |
D014031
|
| PubChem ID |
62005
|
| TTD Drug ID |
D07BCT
|
| NDC Product Code |
42513-0009; 63323-306; 17478-114; 45932-0012; 63552-025; 0409-3578; 63323-303; 51552-0789; 63323-307; 63323-305; 62991-1351; 45932-0014; 10695-008; 49452-7821; 38779-0319 |
| Synonyms |
Tobramycin | Nebramycin Factor 6 | Tobramycin Sulfate | Sulfate, Tobramycin | Obracin | Tobracin | Brulamycin | Nebcin | Nebicin |
